Elevance Health, Inc. (ELV)
Elevance beats quarterly profit estimates on lower-than-expected medical costs
Elevance beat Wall Street estimates for quarterly profit on Thursday, as the health insurer spent less than expected on the medical costs of its members.
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
ELV's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Unveiling Elevance Health (ELV) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Elevance Health (ELV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Elevance Health Is An Undervalued Healthcare Juggernaut
Elevance Health is a strong buy despite a 30% stock decline, due to its solid fundamentals and market position in the health insurance industry. The company benefits from secular trends like an aging population and increased life expectancy, driving long-term demand for healthcare services. Key risks include rising healthcare costs and a shrinking Medicaid member base, impacting margins and free cash flow.
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
ELV is reallocating resources to more profitable areas and making prudent acquisitions.
Elevance Health: A Quality Underpriced Stock Returning To Health
Elevance Health has shown robust financial performance, with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, ELV's long-term fundamentals remain strong, presenting an investment opportunity. ELV's valuation is attractive, with a forward PE of 11.2x, lower than its 10-year average, and potential upside driven by AI integration.
Elevance Health Stock Falls As Anthem Faces Backlash Over Anesthesia Policy, Announces Reversal
When Anthem Blue Cross Blue Shield said it will no longer pay for anesthesia care if the surgery or procedure exceeds an arbitrary time limit, parent company Elevance Health Inc ELV faced backlash and reneged on the policy change.
Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?
ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.
What's Behind The 15% Fall For Elevance Health Stock?
Elevance Health (NYSE: ELV) recently reported its Q3 results, with revenues exceeding but earnings missing the consensus estimates. The company reported revenue of $44.7 billion and adjusted earnings of $8.37 per share, compared to the street estimates of $43.5 billion and $9.66, respectively.
Elevance Health Stock: Looking Beyond Near-Term Issues, I'm A Buyer
Elevance Health's Q3 2024 results were disappointing with a significant increase in the benefit expense ratio and lowered earnings expectations for the full year. I take a close look at ELV's exposure to government plans and their profitability. I explain why I view Elevance stock as favorably valued even under very conservative near and long-term growth assumptions.
These Analysts Cut Their Forecasts On Elevance Health Following Q3 Earnings
Elevance Health Inc. ELV reported weaker-than-expected earnings for its third quarter on Thursday.
S&P 500 Gains and Losses Today: Health Insurers Slide as Elevance Cites Medicaid Declines
Major U.S. equities indexes were mixed as earnings results from Taiwan Semiconductor Manufacturing (TSM) helped revitalize optimism around artificial intelligence (AI) and September retail sales data came in ahead of forecasts.
